|
12 documents found matching dt:press release.
|
|
of 2
Prev
Next
|
|
|
|
Showing 1-10 of 12 documents
|
1.
Press release re FDA grants priority review for Vioxx
|
Document Date:
|
19990111
|
|
Search Terms in Context:
|
^ MERCK News Release
FOR IMMEDIATE RELEASE
Media contact: Rebecca Hig be e ' Investor contact: Laura Jordan
215/652-5S54 908/423-5185
Jan Weiner 215/652*6462
FDA GRANTS PRIORITY REVIEW FOR VIOXX™, MERCK'S INVESTIGATIONAL MEDICINE FOR OSTEOARTHRITIS AND PAIN
WEST POINT
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx04a10
|
|
| |
2.
Press Release - Merck Confirms the CV safety profile of Vioxx
|
Document Date:
|
20000428
|
|
Search Terms in Context:
|
® is the Merck registered trademark (or rofecoxib.
MRK-PRL0000122
^TjEfSÄntsi
1 EXHIBIT
3!
¡NO.D-1447
^—^—^^_______________________________________
Press Release - Merck Confirms Cardiovascular Safety Profile of Viox
•V f Á MERCK
pgNbr=1
Further analyses are ongoing, and final results of the Gl outcomes study with Vioxx will be presented at the Digestive Disease Week meeting
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx17k10
|
|
| |
3.
Press Release re: preliminar results of GI Outcomes Study
|
Document Date:
|
20000327
|
|
Search Terms in Context:
|
News Release
FOR IMMEDIATE RELEASE
Media Contacts: # Investor Contact:
Jan Weiner Mary Elizabeth Basaman Laura Jordan
215/652-6462 215/652-5244 908/423-5185
Merck Informs Investigators of Preliminary
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx15y10
|
|
| |
4.
Press release: Merck Informs Investigators of Preliminary Results of GI Outcomes Study with Vioxx
|
Document Date:
|
20000327
|
|
Search Terms in Context:
|
News Release
FOR IMMEDIATE RELEASE
Media Contacts: _ Investor Contact:
Jan Werner Mary Elizabeth Basarrian Laura Jordan
215/652-6462 215/B52-5244 908/423-5185
Merck Informs Investigators of Preliminary
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx04b10
|
|
| |
5.
Merck Informs Investigators of Preliminary Results of GI Outcomes Study with Vioxx
|
Document Date:
|
20000327
|
|
Search Terms in Context:
|
+4'MERCK
News Release
FOR IMMEDIATE RELEASE
Media Contacts: Jan Weiner 215/652-6462
Mary Elizabeth Basaman 215/652-5244
Investor Contact:
Laura Jordan 908/423-5185
Merck Informs Investigators of Preliminary Results of Gastrointestinal Outcomes Study with VIOXX®
WEST POINT, Pa., March 27, 2000 -- Merck & Co., Inc. today informed its investigators of a preliminary analysis from a large
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx11o10
|
|
| |
6.
CV Safety Profile of Vioxx
|
Document Date:
|
20010522
|
|
Search Terms in Context:
|
t
VI0NEW0H7)
t
News Release'
FOR IMMEDIATE RELEASE
Media Contacts: Jan Weiner • Investor Contact: Laura Jordan
267/305-6462 908/423-5185
Greg Reaves 908/423-6022
Merck Confirms Favorable Cardiovascular Safety Profile of Vioxx®
UPPER GWYNEDD, Pa., May 22, 2001 - In response to news and analyst reports
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx12o10
|
|
| |
7.
Merck News Release - FDA Approves Label Changes
|
Document Date:
|
20020411
|
|
Corporate Author:
|
Merck & Co., Inc
|
|
Search Terms in Context:
|
discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck-Medco manages pharmacy benefits for employers, insurers and other plan sponsors, encouraging the appropriate use of medicines and providing disease management programs.
This press release contains "forward-looking statements
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx02n10
|
|
| |
8.
Merck News Release: In a study of Vioxx published in the NEJM, Vioxx significantly reduced the risk of serious GI side effects by half compared to naproxen
|
Document Date:
|
20001122
|
|
Corporate Author:
|
Merck & Co.
|
|
Search Terms in Context:
|
V *
*+ MERCK News Release
EMBARGOED UNTIL 5 P.M. E.S.T. WEDNESDAY, NOV. 22
Media Contact: Mary Elizabeth Basaman . Investor Contact: Laura Jordan
215/652-5244 908/423-5185
In a study of Vioxx® published in The New England Journal of Medicine, Vioxx significantly reduced
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx03d10
|
|
| |
9.
In a study of Vioxx published in the New England Journal of Medicine, Vioxx significantly reduced the risk of serious gastrointestinal side effects by half compared to Naproxen
|
Document Date:
|
20001122
|
|
Author:
|
Bassaman|Jordan
|
|
Search Terms in Context:
|
News Release
EMBARGOED UNTIL 5 P.M. E.S.T. WEDNESDAY, NOV. 22
Media Contact: Mary Elizabeth Basaman . Investor Contact: Laura Jordan
215/652-5244 908/423-5185
In a study of Vioxx® published in The Nev/ England Journal of Medicine,
Vioxx significantly reduced the risk of serious gastrointestinal side
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx08y10
|
|
| |
10.
Vioxx significantly reduced the risk of serious gastrointenstinal side effects by more than half compared to naproxen in a new study
|
Document Date:
|
20000524
|
|
Search Terms in Context:
|
MERCK News Release
Media Contacts: Jan Weiner Investor Contact: Laura Jordan
215/652-6462 908/423-5185
Mary Elizabeth Basaman 215/652-5244
Vioxx® significantly reduced the risk of serious gastrointestinal side effects by more than half compared
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx13x10
|
|
| |
|
Prev
Next
|
